BIOVAXYS AND BIOELPIDA SIGN DEFINITIVE EXCLUSIVE AGREEMENT TO BEGIN OVARIAN CANCER VACCINE BIOPRODUCTION

Vancouver, BC – May 3, 2021 —  BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) (“BioVaxys” or “Company”) announced today that it has signed the definitive exclusive bioproduction agreement (“Agreement”) with BioElpida S.A.S. (“BioElpida”) of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys’ vaccine candidate for Stage III/Stage IV ovarian […]